Cart
sales@molnova.com
JAK-IN-35
CAS No. 1400687-19-5
JAK-IN-35( —— )
Catalog No. M11669 CAS No. 1400687-19-5
JAK-IN-35 is a potent and efficacious dual JAK1/JAK3 inhibitor with IC50 of 0.9/1.9 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameJAK-IN-35
-
NoteResearch use only, not for human use.
-
Brief DescriptionJAK-IN-35 is a potent and efficacious dual JAK1/JAK3 inhibitor with IC50 of 0.9/1.9 nM.
-
DescriptionJAK-IN-35 is a potent and efficacious dual JAK1/JAK3 inhibitor with IC50 of 0.9/1.9 nM; shows weak activity against TYK2 and JAK2 (IC50=25 nM and15 nM respectively), also inhibits both ROCK1 (IC50=95 nM) and ROCK2 (IC50=43 nM); inhibits JAK1/3 mediated ex vivo processes in the mouse PD model (EC50 67 ± 13 nM); shows potential cardiovascular liabilities, specifically, QT interval prolongation.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorJAK
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number1400687-19-5
-
Formula Weight408.506
-
Molecular FormulaC22H28N6O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC1(C(CCC1(C)N)NC2=C(C=NN3C2=CC(=C3)C4=CN=C(C=C4)OC)C(=O)N)C
-
Chemical Name4-(((1R,3S)-3-amino-2,2,3-trimethylcyclopentyl)amino)-6-(6-methoxypyridin-3-yl)pyrrolo[1,2-b]pyridazine-3-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hynes J Jr, et al. Bioorg Med Chem Lett. 2017 Jul 15;27(14):3101-3106.
molnova catalog
related products
-
PF-06700841
PF-06700841 is a potent, selective TYK2/JAK1 kinase inhibitor that reduces IL-23 expression and directly attenuates IL-23 signaling via TYK2.
-
WHI-P97
A potent, specific JAK3 inhibitor with Ki of 0.6-2.3 uM.
-
BMS-986165
BMS-986165 is differentiated from previous JAK inhibitors due its unique ability to selectively bind to the pseudokinase (JH2) domain of TYK2 and inhibit its function through an allosteric mechanism.
